inSoma Bio
YC S20Durham, US · Founded 2018 · Delaware corporation · 4 employees · 3 known investors
Find your way into inSoma Bio
162 people in our graph share verified history with the inSoma Bio team — schools, employers, funds. One of them is your warm intro.
Pae Wuunlockedknows Ashutosh Chilkoti · together at Duke University (overlapped)
×11knows the team · via Duke University
inSoma Bio develops biomaterial products for reconstruction plastic surgery, enabling surgeons to use patients' own tissue instead of synthetic implants and fillers for breast and facial reconstruction procedures.
Founders & leadership· Y Combinator alumni (S20)
inSoma Bio was founded in 2018 by Stefan Roberts and Ashutosh Chilkoti.
SR
Stefan RobertsinChief Executive Officer
AC
Ashutosh ChilkotiinChairmanAshutosh Chilkoti is a Biomedical Engineering professor and department chair at Duke University with research focus on genetically encoded biomaterials, drug delivery, and point-of-care diagnostics. He has cofounded five companies including PhaseBio, Sentilus, Gateway Bio, Isolere Bio, and inSoma Bio.
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$6.9M disclosed across 4 rounds · 2020–2025
▶$2.7MraisedJan 2026 · 15 investors · BiotechnologyRule 506(b)
▶$2.7MraisedJan 2026 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ashutosh ChilkotiExecutive Officer, Director
- Juliana BlumDirector
- Stefan RobertsExecutive Officer, Director
- Heather BrennanDirector
- June S. AlmenoffDirector
- Offering amount
- $4M
- Amount sold
- $2.7M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedMay 2024 · 16 investors · BiotechnologyRule 506(b)
▶$2.7MraisedMay 2024 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- June S. AlmenoffDirector
- Stefan RobertsExecutive Officer, Director
- Juliana BlumDirector
- Ashutosh ChilkotiExecutive Officer, Director
- Heather BrennanDirector
- Offering amount
- $3M
- Amount sold
- $2.7M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedDec 2020 · 31 investors · BiotechnologyRule 506(b)
▶$1.3MraisedDec 2020 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ashutosh ChilkotiExecutive Officer, Director
- Stefan RobertsExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.3M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$202KraisedJul 2020 · 7 investors · BiotechnologyRule 506(b)
▶$202KraisedJul 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stefan E. RobertsExecutive Officer, Director
- Ashutosh ChilkotiExecutive Officer, Director
- Offering amount
- $202K
- Amount sold
- $202K
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapEnsoma3 shared keywordsEnsoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment. Its technology aims to selectively and durably modify cells of the hematopoietic system for patients.
Sonoma Biotherapeutics3 shared keywordsSonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases. The company uses proprietary platform technologies to create targeted and durable Treg cell therapies.
OrsoBio3 shared keywordsOrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways. The company targets patients with metabolic diseases through precision therapeutic approaches.
Companies competing with inSoma Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does inSoma Bio do?
- inSoma Bio develops biomaterial products for reconstruction plastic surgery, enabling surgeons to use patients' own tissue instead of synthetic implants and fillers for breast and facial reconstruction procedures.
- Who founded inSoma Bio?
- inSoma Bio was founded by Stefan Roberts, Ashutosh Chilkoti in 2018.
- Who are inSoma Bio's investors?
- inSoma Bio's investors include Duke Capital Partners, FemHealth Ventures, Y Combinator.
- How much funding has inSoma Bio raised?
- inSoma Bio has disclosed $6.9M raised across 4 rounds.
- Where is inSoma Bio headquartered?
- inSoma Bio is headquartered in Durham, US.